José María Echave-Sustaeta Maria-Tome
José María Echave-Sustaeta Maria-Tome
JEFE/A DE SERVICIO
Neumologíaes/especialidades/neumologia
Ver más especialistas en
Madridmadrid
es/cuadro-medico/neumologo
Datos destacados
- Última publicación:Characterization of COPD Admissions During the First COVID-19 Outbreak.
Datos del profesional
Hospital Universitario Quirónsalud Madrid
JEFE/A DE SERVICIO
Enero 2007
Hospital Universitario Ruber Juan Bravo
JEFE/A DE SERVICIO
Junio 2016
Hospital Universitario Ruber Juan Bravo
JEFE/A DE SERVICIO
Junio 2016
Hospital Quirónsalud Valle del Henares
JEFE/A DE SERVICIO
Abril 2021
Hospital Universitario La Luz
JEFE/A DE SERVICIO
Marzo 2017
Olympia Centro Médico Pozuelo
JEFE/A DE SERVICIO
Septiembre 2025
Centro Médico Quirónsalud Valle del Henares
JEFE/A DE SERVICIO
Abril 2021
Centro médico-quirúrgico Olympia
JEFE/A DE SERVICIO
Enero 2023
Characterization of COPD Admissions During the First COVID-19 Outbreak.
Journal Article, Research Support, Non-U.S. Govt
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).
Journal Article
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
Journal Article, Research Support, Non-U.S. Govt
InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
Journal Article
Inhaler Adherence in COPD: A Crucial Step Towards the Correct Treatment.
Journal Article, Review
Microspirometers in the Follow-Up of COPD: Advantages and Disadvantages.
Editorial
The ANTES program in COPD: First year.
Editorial
Time for a change: anticipating the diagnosis and treatment of COPD.
Editorial, Research Support, Non-U.S. Govt
